# EDGAR Filing Document

**Accession Number:** 0001652130
**File Stem:** 0001193125-26-077385
**Filing Date:** 2026-2
**Character Count:** 19055
**Document Hash:** 5a45426b1fe29fb3db7a282ecfe60836
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-077385.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001193125-26-077385

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**EFFECTIVENESS DATE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Intellia Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001652130
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 364785571
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293823
- **FILM NUMBER:** 26690704

**BUSINESS ADDRESS:**
- **STREET 1:** 40 ERIE STREET
- **STREET 2:** SUITE 130
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 857-285-6200

**MAIL ADDRESS:**
- **STREET 1:** 40 ERIE STREET
- **STREET 2:** SUITE 130
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**As filed with the Securities and Exchange Commission on February 26, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Intellia Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37766** | **36-4785571** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |
| **40 Erie Street, Suite 130**<br> **Cambridge, Massachusetts** |  | **02139** |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Intellia Therapeutics, Inc. 2024 Inducement Plan** 

**Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan** 

**(Full title of the plan)** 

**John Leonard, M.D.** 

**President and Chief Executive Officer** 

**40 Erie Street, Suite 130** 

**Cambridge, Massachusetts 02139** 

**(857) 285-6200** 

**(Name, address and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Michael H. Bison, Esq.**<br> **Gabriela Morales-Rivera, Esq.**<br> **Goodwin Procter LLP**<br> **100 Northern Ave.**<br> **Boston, Massachusetts 02210**<br> **(617) 570-1000** | **James Basta, Esq.**<br> **Executive Vice President, General Counsel**<br> **Intellia Therapeutics, Inc.**<br> **40 Erie Street, Suite 130**<br> **Cambridge, Massachusetts 02139**<br> **(857) 285-6200** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**Explanatory Note** 

This Registration Statement on Form S-8 is filed to register the offer and sale of (i) an additional 1,500,000 shares of the Registrant's common stock, $0.0001 par value per share (the "Common Stock"), to be issued under the Registrant's 2024 Inducement Plan, as amended (the "Inducement Plan"), and (ii) an additional 500,000 shares of Common Stock to be issued under the Registrant's 2016 Employee Stock Purchase Plan (the "2016 ESPP").

On December 4, 2025, the board of directors of Intellia Therapeutics, Inc. (the "Registrant") approved an amendment to the Inducement Plan pursuant to which the Registrant reserved an additional 1,500,000 shares of Common Stock to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Registrant, as an inducement material to the individual's entry into employment with the Registrant within the meaning of Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market. The Inducement Plan provides for the grant of equity-based awards in the form of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, unrestricted stock awards, and dividend equivalent rights. The Inducement Plan was adopted by the Registrant's board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market.

On January 1, 2026, pursuant to the terms of the 2016 ESPP, the Annual Increase (as defined in the 2016 ESPP), comprising 500,000 shares of Common Stock, was added to the reserve available for issuance under the 2016 ESPP.

**Statement of Incorporation by Reference** 

Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 filed by the Registrant on May 6, 2016 ([File No. 333-211200](http://www.sec.gov/Archives/edgar/data/1652130/000119312516582025/d187899ds8.htm)), June 5, 2017 ([File No 333-218511](http://www.sec.gov/Archives/edgar/data/1652130/000119312517194765/d380820ds8.htm)), February 27, 2019 ([File No. 333-229900](http://www.sec.gov/Archives/edgar/data/1652130/000119312519052972/d715362ds8.htm)), July 18, 2024 ([File No. 333-280878](http://www.sec.gov/Archives/edgar/data/1652130/000119312524181015/d873156ds8.htm)), and February 28, 2025 ([File No. 333-285414](http://www.sec.gov/Archives/edgar/data/1652130/000119312525042458/d935377ds8.htm)) related to the Registrant's Inducement Plan and 2016 ESPP, as applicable, are incorporated by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier Registration Statements are presented herein.

------

**Part II** 

**Information Required in the Registration Statement** 

Item 8. Exhibits.

See the Exhibit Index below for a list of exhibits filed as part of this registration statement on Form S-8, which Exhibit Index is incorporated herein by reference.

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Number** | **Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K (File No. 001-37766) filed with the Securities and Exchange Commission on May 17, 2016)](http://www.sec.gov/Archives/edgar/data/1652130/000119312516593332/d194360dex41.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K (File No. 001-37766) filed with the Securities and Exchange Commission on February 27, 2025)](http://www.sec.gov/Archives/edgar/data/1652130/000095017025029007/ntla-ex3_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Third Amended and Restated By-laws of the Registrant, dated April 3, 2025 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-37766) filed with the Securities and Exchange Commission on April 7, 2025)](http://www.sec.gov/Archives/edgar/data/1652130/000119312525073904/d901196dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Goodwin Procter LLP](d119130dex51.htm) |
| 23.1\* | [Consent of Goodwin Procter LLP (included in Exhibit 5.1)](d119130dex51.htm) |
| 23.2\* | [Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm](d119130dex232.htm) |
| 24.1\* | [Power of attorney (included on the signature pages of this registration statement)](d119130ds8.htm#sig) |
| 99.1 | [2024 Inducement Plan (incorporated by reference to Exhibit 10.30 to the Registrant's Annual Report on Form 10-K (File No. 001-37766) filed with the Securities and Exchange Commission on February 27, 2025)](http://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/d822257dex102.htm) |
| 99.2 | [Amendment No. 1 to the Registrant's 2024 Inducement Plan, effective as of December 4, 2025 (incorporated by reference to Exhibit 10.29 to the Registrant's Annual Report on Form 10-K (File No. 001-37766) filed with the Securities and Exchange Commission on February 26, 2026).](http://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-ex10_29.htm) |
| 99.3 | [2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 to the Registrant's Annual Report on Form 10-K (File No. 001-37766) filed with the Securities and Exchange Commission on February 26, 2026)](http://www.sec.gov/Archives/edgar/data/1652130/000119312516558271/d67753dex109.htm) |
| 107.1\* | [Filing Fee Table.](d119130dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 26th day of February, 2026.

---

| | |
|:---|:---|
| INTELLIA THERAPEUTICS, INC. | INTELLIA THERAPEUTICS, INC. |
| By: | /s/ John Leonard |
|  | John Leonard, M.D. |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES** 

KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of John Leonard, M.D., James Basta, J.D. and Edward Dulac as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

------

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ John M. Leonard<br> John M. Leonard, M.D. | President, Chief Executive Officer and Director<br>*(Principal Executive Officer)* | February 26, 2026 |
| /s/ Edward J. Dulac III<br> Edward J. Dulac III | Executive Vice President, Chief Financial Officer<br>*(Principal Financial Officer)* | February 26, 2026 |
| /s/ Michael P. Dube<br> Michael P. Dube | Vice President, Chief Accounting Officer<br>*(Principal Accounting Officer)* | February 26, 2026 |
| /s/ Muna Bhanji<br> Muna Bhanji | Director | February 26, 2026 |
| /s/ Bill Chase<br> Bill Chase | Director | February 26, 2026 |
| /s/ Fred Cohen<br> Fred Cohen, M.D. | Director | February 26, 2026 |
| /s/ Brian Goff<br> Brian Goff | Director | February 26, 2026 |
| /s/ Jesse Goodman<br> Jesse Goodman, M.D. | Director | February 26, 2026 |
| /s/ Georgia Keresty<br> Georgia Keresty | Director | February 26, 2026 |
| /s/ Frank Verwiel<br> Frank Verwiel, M.D. | Director | February 26, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1** 

February 26, 2026

Intellia Therapeutics, Inc.

40 Erie Street, Suite 130

Cambridge, Massachusetts 02139

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 2,000,000 shares (the "Shares") of Common Stock, par value $0.0001 per share ("Common Stock"), of Intellia Therapeutics, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's 2016 Employee Stock Purchase Plan and the Company's 2024 Inducement Plan, as amended (collectively, the "Plans").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
|  Very truly yours, |
|  /s/ Goodwin Procter LLP |
|  GOODWIN PROCTER LLP |

---

## Exhibit 23.2

**Exhibit 23.2** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated February 26, 2026, relating to the financial statements of Intellia Therapeutics, Inc. and the effectiveness of Intellia Therapeutics, Inc.'s internal control over financial reporting, appearing in the Annual Report on Form 10-K of Intellia Therapeutics, Inc. for the year ended December 31, 2025.

---

| |
|:---|
| /s/ Deloitte & Touche LLP |
| Boston, Massachusetts |
| February 26, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Intellia Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to Amendment No. 1 to the Intellia Therapeutics, Inc. 2024 Inducement Plan | Other | 1500000 | $12.74 | $19110000.00 | 0.0001381 | $2639.10 |
| 2 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan | Other | 500000 | $10.83 | $5415000.00 | 0.0001381 | $747.82 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $24525000.00  |  | $3386.92  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $3386.92  |

---

 **Offering Note** <br>

<sup>1</sup> (1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. (2) Represents an increase to the number of shares available for issuance under Amendment No. 1 to the 2024 Inducement Plan (the "Inducement Plan") of 1,500,000 effective as of January 1, 2026. Shares available for issuance under the Inducement Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on July 18, 2024 (File No. 333-280878). (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of $12.74 , the average of the high and low price of the Registrant's Common Stock as reported on the NASDAQ Global Market on February 20, 2026.

<sup>2</sup> (4) Represents an automatic increase to the number of shares available for issuance under the 2016 Employee Stock Purchase Plan (the "ESPP"), of 500,000 effective as of January 1, 2026. Shares available for issuance under the ESPP were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on May 6, 2016 (File No. 333-21200), June 5, 2017 (File No. 333-218511), February 27, 2019 (File No. 333-229900), and February 28, 2025 (File No. 333-285414). (5) The price of $10.83 per share, which is 85% of the average of the high and low sale prices of the registrant's Common Stock as reported on the NASDAQ Global Market on February 20, 2026, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act of 1933, as amended, and has been used as these shares are without a fixed price. Pursuant to the ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the fair market value of a share of Common Stock on the first trading day of the offering period or on the exercise date, whichever is less.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---